;PMID: 10216279
;source_file_1897.mrg
;Release 0.9 of PennBioIE
;Funded by NSF ITR EIA-0205448

;0)section:[e:0..48] = [t:0..48]
;1)sentence:[e:54..163] = [t:54..163]
;2)section:[e:167..186] = [t:167..186]
;3)section:[e:190..343] = [t:190..343]
;4)sentence:[e:347..460] = [t:347..460]
;5)sentence:[e:461..701] = [t:461..701]
;6)sentence:[e:702..910] = [t:702..910]
;7)sentence:[e:911..1048] = [t:911..1048]
;8)sentence:[e:1050..1098] = [t:1050..1098]
;9)sentence:[e:1099..1292] = [t:1099..1292]
;10)sentence:[e:1294..1456] = [t:1294..1456]
;11)sentence:[e:1457..1604] = [t:1457..1604]
;12)sentence:[e:1605..1771] = [t:1605..1771]
;13)sentence:[e:1772..1902] = [t:1772..1902]
;14)sentence:[e:1903..2018] = [t:1903..2018]
;15)sentence:[e:2019..2130] = [t:2019..2130]
;16)sentence:[e:2131..2300] = [t:2131..2300]
;17)section:[e:2304..2349] = [t:2304..2349]

;section 0 Span:0..48
;Biochim Biophys Acta. 1999 Apr 19;1438(1):47-54.
(SEC
  (FRAG (NNP:[0..7] Biochim) (NNP:[8..15] Biophys) (NNP:[16..20] Acta)
        (.:[20..21] .) (CD:[22..26] 1999) (CC:[27..30] Apr)
        (CD:[31..38] 19;1438) (-LRB-:[38..39] -LRB-) (CD:[39..40] 1)
        (-RRB-:[40..41] -RRB-) (CD:[41..44] :47) (::[44..45] -) (CD:[45..47] 54)
        (.:[47..48] .)))

;sentence 1 Span:54..163
;6alpha-hydroxylation of taurochenodeoxycholic acid and lithocholic acid by 
;CYP3A4 in human liver microsomes.
;[78..104]:substance:"taurochenodeoxycholic acid"
;[109..125]:substance:"lithocholic acid"
;[130..136]:cyp450:"CYP3A4"
(SENT
  (NP-HLN
    (NP (NN:[54..74] 6alpha-hydroxylation))
    (PP (IN:[75..77] of)
      (NP
        (NP (JJ:[78..99] taurochenodeoxycholic) (NN:[100..104] acid))
        (CC:[105..108] and)
        (NP (JJ:[109..120] lithocholic) (NN:[121..125] acid))))
    (PP (IN:[126..128] by)
      (NP (NN:[130..136] CYP3A4)))
    (PP-LOC (IN:[137..139] in)
      (NP (JJ:[140..145] human) (NN:[146..151] liver)
          (NNS:[152..162] microsomes)))
    (.:[162..163] .)))

;section 2 Span:167..186
;Araya Z, Wikvall K.
(SEC
  (FRAG (NNP:[167..172] Araya) (NNP:[173..174] Z) (,:[174..175] ,)
        (NNP:[176..183] Wikvall) (NNP:[184..186] K.)))

;section 3 Span:190..343
;Division of Biochemistry, Department of Pharmaceutical Biosciences,
;University  of Uppsala, Box 578, S-751 23, Uppsala, Sweden.
;zufan.araya@farmbio.uu.se
(SEC
  (FRAG (NNP:[190..198] Division) (IN:[199..201] of)
        (NNP:[202..214] Biochemistry) (,:[214..215] ,)
        (NNP:[216..226] Department) (IN:[227..229] of)
        (NNP:[230..244] Pharmaceutical) (NNP:[245..256] Biosciences)
        (,:[256..257] ,) (NNP:[258..268] University) (IN:[270..272] of)
        (NNP:[273..280] Uppsala) (,:[280..281] ,) (NNP:[282..285] Box)
        (CD:[286..289] 578) (,:[289..290] ,) (NN:[291..293] S-)
        (CD:[293..296] 751) (CD:[297..299] 23) (,:[299..300] ,)
        (NNP:[301..308] Uppsala) (,:[308..309] ,) (NNP:[310..316] Sweden)
        (.:[316..317] .) (NNP:[318..323] zufan)
        (VBD:[323..343] .araya@farmbio.uu.se)))

;sentence 4 Span:347..460
;The aim of the present study was to identify the enzymes in human liver 
;catalyzing hydroxylations of bile acids.
;[396..403]:substance:"enzymes"
;[449..459]:substance:"bile acids"
(SENT
  (S
    (NP-SBJ-1
      (NP (DT:[347..350] The) (NN:[351..354] aim))
      (PP (IN:[355..357] of)
        (NP (DT:[358..361] the) (JJ:[362..369] present) (NN:[370..375] study))))
    (VP (VBD:[376..379] was)
      (S-PRP-PRD
        (NP-SBJ-1 (-NONE-:[379..379] *))
        (VP (TO:[380..382] to)
          (VP (VB:[383..391] identify)
            (NP
              (NP (DT:[392..395] the) (NNS:[396..403] enzymes))
              (PP-LOC (IN:[404..406] in)
                (NP
                  (NP
                    (ADJP
                      (NML (JJ:[407..412] human) (NN:[413..418] liver))
                      (VBG:[420..430] catalyzing))
                    (NNS:[431..445] hydroxylations))
                  (PP (IN:[446..448] of)
                    (NP (NN:[449..453] bile) (NNS:[454..459] acids))))))))))
    (.:[459..460] .)))

;sentence 5 Span:461..701
;Fourteen recombinant expressed  cytochrome P450 (CYP) enzymes, human liver
;microsomes from different donors, and  selective cytochrome P450 inhibitors
;were used to study the hydroxylation of  taurochenodeoxycholic acid and
;lithocholic acid.
;[493..522]:cyp450:"cytochrome P450 (CYP) enzymes"
;[585..600]:cyp450:"cytochrome P450"
;[601..611]:substance:"inhibitors"
;[653..679]:substance:"taurochenodeoxycholic acid"
;[684..700]:substance:"lithocholic acid"
(SENT
  (S
    (NP-SBJ-1
      (NP (CD:[461..469] Fourteen)
        (ADJP (JJ:[470..481] recombinant) (VBN:[482..491] expressed))
        
        (NML
          (NML (NN:[493..503] cytochrome) (NN:[504..508] P450))
          (NML (-LRB-:[509..510] -LRB-) (NN:[510..513] CYP)
               (-RRB-:[513..514] -RRB-)))
        (NNS:[515..522] enzymes))
      (,:[522..523] ,)
      (NP
        (NP (JJ:[524..529] human) (NN:[530..535] liver)
            (NNS:[536..546] microsomes))
        (PP (IN:[547..551] from)
          (NP (JJ:[552..561] different) (NNS:[562..568] donors))))
      (,:[568..569] ,) (CC:[570..573] and)
      (NP (JJ:[575..584] selective)
        (NML (NN:[585..595] cytochrome) (NN:[596..600] P450))
        (NNS:[601..611] inhibitors)))
    (VP (VBD:[612..616] were)
      (VP (VBN:[617..621] used)
        (NP-1 (-NONE-:[621..621] *))
        (S-PRP
          (NP-SBJ-1 (-NONE-:[621..621] *))
          (VP (TO:[622..624] to)
            (VP (VB:[625..630] study)
              (NP
                (NP (DT:[631..634] the) (NN:[635..648] hydroxylation))
                (PP (IN:[649..651] of)
                  (NP
                    (NP (JJ:[653..674] taurochenodeoxycholic)
                        (NN:[675..679] acid))
                    (CC:[680..683] and)
                    (NP (JJ:[684..695] lithocholic) (NN:[696..700] acid))))))))))
    (.:[700..701] .)))

;sentence 6 Span:702..910
;Recombinant expressed CYP3A4  was the only enzyme that was active towards
;these bile acids and the enzyme  catalyzed an efficient 6alpha-hydroxylation
;of both taurochenodeoxycholic acid  and lithocholic acid.
;[724..730]:cyp450:"CYP3A4"
;[745..751]:cyp450:"enzyme"
;[782..792]:substance:"bile acids"
;[801..807]:substance:"enzyme"
;[861..887]:substance:"taurochenodeoxycholic acid"
;[893..909]:substance:"lithocholic acid"
(SENT
  (S
    (S
      (NP-SBJ (JJ:[702..713] Recombinant) (VBN:[714..723] expressed)
              (NN:[724..730] CYP3A4))
      (VP (VBD:[732..735] was)
        (NP-PRD
          (NP (DT:[736..739] the) (RB:[740..744] only) (NN:[745..751] enzyme))
          (SBAR
            (WHNP-1 (WDT:[752..756] that))
            (S
              (NP-SBJ-1 (-NONE-:[756..756] *T*))
              (VP (VBD:[757..760] was)
                (ADJP-PRD (JJ:[761..767] active)
                  (PP (IN:[768..775] towards)
                    (NP (DT:[776..781] these)
                       (NN:[782..786] bile) (NNS:[787..792] acids))))))))))
    (CC:[793..796] and)
    (S
      (NP-SBJ (DT:[797..800] the) (NN:[801..807] enzyme))
      (VP (VBD:[809..818] catalyzed)
        (NP
          (NP (DT:[819..821] an) (JJ:[822..831] efficient)
              (NN:[832..852] 6alpha-hydroxylation))
          (PP (IN:[853..855] of)
            (NP (CC:[856..860] both)
              (NP (JJ:[861..882] taurochenodeoxycholic) (NN:[883..887] acid))
              (CC:[889..892] and)
              (NP (JJ:[893..904] lithocholic) (NN:[905..909] acid)))))))
    (.:[909..910] .)))

;sentence 7 Span:911..1048
;The Vmax for 6alpha-hydroxylation of taurochenodeoxycholic  acid by CYP3A4
;was 18.2 nmol/nmol P450/min and the apparent Km was 90 microM.
;[915..919]:quantitative-name:"Vmax"
;[948..975]:substance:"taurochenodeoxycholic  acid"
;[979..985]:cyp450:"CYP3A4"
;[990..994]:quantitative-value:"18.2"
;[995..1013]:quantitative-units:"nmol/nmol P450/min"
;[1031..1033]:quantitative-name:"Km"
;[1038..1040]:quantitative-value:"90"
;[1041..1047]:quantitative-units:"microM"
(SENT
  (S
    (S
      (NP-SBJ
        (NP (DT:[911..914] The) (NN:[915..919] Vmax))
        (PP (IN:[920..923] for)
          (NP
            (NP (NN:[924..944] 6alpha-hydroxylation))
            (PP (IN:[945..947] of)
              (NP (JJ:[948..969] taurochenodeoxycholic) (NN:[971..975] acid)))
            (PP (IN:[976..978] by)
              (NP (NN:[979..985] CYP3A4))))))
      (VP (VBD:[986..989] was)
        (NP-PRD
          (NP (CD:[990..994] 18.2) (NN:[995..999] nmol))
          (PP (SYM:[999..1000] /)
            (NP (NN:[1000..1004] nmol) (NN:[1005..1009] P450)))
          (PP (SYM:[1009..1010] /)
            (NP (NN:[1010..1013] min))))))
    (CC:[1014..1017] and)
    (S
      (NP-SBJ (DT:[1018..1021] the) (JJ:[1022..1030] apparent)
              (NN:[1031..1033] Km))
      (VP (VBD:[1034..1037] was)
        (NP-PRD (CD:[1038..1040] 90) (NN:[1041..1047] microM))))
    (.:[1047..1048] .)))

;sentence 8 Span:1050..1098
;Cytochrome b5 was required for maximal activity.
;[1050..1063]:cyp450:"Cytochrome b5"
(SENT
  (S
    (NP-SBJ-1 (NN:[1050..1060] Cytochrome) (NN:[1061..1063] b5))
    (VP (VBD:[1064..1067] was)
      (VP (VBN:[1068..1076] required)
        (NP-1 (-NONE-:[1076..1076] *))
        (PP-PRP (IN:[1077..1080] for)
          (NP (JJ:[1081..1088] maximal) (NN:[1089..1097] activity)))))
    (.:[1097..1098] .)))

;sentence 9 Span:1099..1292
;Human liver microsomes from 10  different donors, in which different P450
;marker activities had been determined,  were separately incubated with
;taurochenodeoxycholic acid and lithocholic acid.
;[1168..1172]:cyp450:"P450"
;[1244..1270]:substance:"taurochenodeoxycholic acid"
;[1275..1291]:substance:"lithocholic acid"
(SENT
  (S
    (NP-SBJ-3
      (NP
        (NP (JJ:[1099..1104] Human) (NN:[1105..1110] liver)
            (NNS:[1111..1121] microsomes))
        (PP (IN:[1122..1126] from)
          (NP (CD:[1127..1129] 10) (JJ:[1131..1140] different)
              (NNS:[1141..1147] donors))))
      (,:[1147..1148] ,)
      (SBAR
        (WHPP-2 (IN:[1149..1151] in)
          (WHNP (WDT:[1152..1157] which)))
        (S
          (NP-SBJ-1 (JJ:[1158..1167] different) (NN:[1168..1172] P450)
                    (NN:[1173..1179] marker) (NNS:[1180..1190] activities))
          (VP (VBD:[1191..1194] had)
            (VP (VBN:[1195..1199] been)
              (VP (VBN:[1200..1210] determined)
                (NP-1 (-NONE-:[1210..1210] *))
                (PP-LOC-2 (-NONE-:[1210..1210] *T*))))))))
    (,:[1210..1211] ,)
    (VP (VBD:[1213..1217] were)
      (ADVP (RB:[1218..1228] separately))
      (VP (VBN:[1229..1238] incubated)
        (NP-3 (-NONE-:[1238..1238] *))
        (PP-MNR (IN:[1239..1243] with)
          (NP
            (NP (JJ:[1244..1265] taurochenodeoxycholic) (NN:[1266..1270] acid))
            (CC:[1271..1274] and)
            (NP (JJ:[1275..1286] lithocholic) (NN:[1287..1291] acid))))))
    (.:[1291..1292] .)))

;sentence 10 Span:1294..1456
;A strong correlation was found between 6alpha-hydroxylation of 
;taurochenodeoxycholic acid, CYP3A levels (r2=0.97) and testosterone 
;6beta-hydroxylation (r2=0.9).
;[1358..1384]:substance:"taurochenodeoxycholic acid"
;[1386..1391]:cyp450:"CYP3A"
;[1413..1425]:substance:"testosterone"
(SENT
  (S
    (NP-SBJ-1
      (NP (DT:[1294..1295] A) (JJ:[1296..1302] strong)
          (NN:[1303..1314] correlation))
      (PP-2 (-NONE-:[1314..1314] *ICH*)))
    (VP (VBD:[1315..1318] was)
      (VP (VBN:[1319..1324] found)
        (NP-1 (-NONE-:[1324..1324] *))
        (PP-2 (IN:[1325..1332] between)
          (NP
            (NP
              (NP (NN:[1333..1353] 6alpha-hydroxylation))
              (PP (IN:[1354..1356] of)
                (NP (JJ:[1358..1379] taurochenodeoxycholic)
                    (NN:[1380..1384] acid))))
            (,:[1384..1385] ,)
            (NP
              (NP (NN:[1386..1391] CYP3A) (NNS:[1392..1398] levels))
              (PRN (-LRB-:[1399..1400] -LRB-)
                (S
                  (NP-SBJ (NN:[1400..1402] r2))
                  (VP (SYM:[1402..1403] =)
                    (NP (CD:[1403..1407] 0.97))))
                (-RRB-:[1407..1408] -RRB-)))
            (CC:[1409..1412] and)
            (NP
              (NP (NN:[1413..1425] testosterone)
                  (NN:[1427..1446] 6beta-hydroxylation))
              (PRN (-LRB-:[1447..1448] -LRB-)
                (S
                  (NP-SBJ (NN:[1448..1450] r2))
                  (VP (SYM:[1450..1451] =)
                    (NP (CD:[1451..1454] 0.9))))
                (-RRB-:[1454..1455] -RRB-)))))))
    (.:[1455..1456] .)))

;sentence 11 Span:1457..1604
;There was also a strong correlation between  6alpha-hydroxylation of
;lithocholic acid, CYP3A levels and testosterone  6beta-hydroxylation
;(r2=0.7).
;[1526..1542]:substance:"lithocholic acid"
;[1544..1549]:cyp450:"CYP3A"
;[1561..1573]:substance:"testosterone"
(SENT
  (S
    (NP-SBJ (EX:[1457..1462] There))
    (VP (VBD:[1463..1466] was)
      (ADVP (RB:[1467..1471] also))
      (NP-PRD
        (NP (DT:[1472..1473] a) (JJ:[1474..1480] strong)
            (NN:[1481..1492] correlation))
        (PP (IN:[1493..1500] between)
          (NP
            (NP
              (NP (NN:[1502..1522] 6alpha-hydroxylation))
              (PP (IN:[1523..1525] of)
                (NP (JJ:[1526..1537] lithocholic) (NN:[1538..1542] acid))))
            (,:[1542..1543] ,)
            (NP (NN:[1544..1549] CYP3A) (NNS:[1550..1556] levels))
            (CC:[1557..1560] and)
            (NP (NN:[1561..1573] testosterone)
                (NN:[1575..1594] 6beta-hydroxylation))
            (PRN (-LRB-:[1595..1596] -LRB-)
              (S
                (NP-SBJ (NN:[1596..1598] r2))
                (VP (SYM:[1598..1599] =)
                  (NP (CD:[1599..1602] 0.7))))
              (-RRB-:[1602..1603] -RRB-))))))
    (.:[1603..1604] .)))

;sentence 12 Span:1605..1771
;Troleandomycin, a selective inhibitor of CYP3A  enzymes, inhibited
;6alpha-hydroxylation of taurochenodeoxycholic acid almost  completely at a 10
;microM concentration.
;[1605..1619]:substance:"Troleandomycin"
;[1633..1642]:substance:"inhibitor"
;[1646..1660]:cyp450:"CYP3A  enzymes"
;[1696..1722]:substance:"taurochenodeoxycholic acid"
;[1747..1749]:quantitative-value:"10"
;[1750..1756]:quantitative-units:"microM"
(SENT
  (S
    (NP-SBJ
      (NP (NN:[1605..1619] Troleandomycin))
      (,:[1619..1620] ,)
      (NP
        (NP (DT:[1621..1622] a) (JJ:[1623..1632] selective)
            (NN:[1633..1642] inhibitor))
        (PP (IN:[1643..1645] of)
          (NP (NN:[1646..1651] CYP3A) (NNS:[1653..1660] enzymes)))))
    (,:[1660..1661] ,)
    (VP (VBD:[1662..1671] inhibited)
      (NP
        (NP (NN:[1672..1692] 6alpha-hydroxylation))
        (PP (IN:[1693..1695] of)
          (NP (JJ:[1696..1717] taurochenodeoxycholic) (NN:[1718..1722] acid))))
      (ADVP (RB:[1723..1729] almost) (RB:[1731..1741] completely))
      (PP (IN:[1742..1744] at)
        (NP (DT:[1745..1746] a)
          (NML (CD:[1747..1749] 10) (NN:[1750..1756] microM))
          (NN:[1757..1770] concentration))))
    (.:[1770..1771] .)))

;sentence 13 Span:1772..1902
;Other inhibitors, such as  alpha-naphthoflavone, sulfaphenazole and
;tranylcypromine had very little or no  effect on the activity.
;[1778..1788]:substance:"inhibitors"
;[1799..1819]:substance:"alpha-naphthoflavone"
;[1821..1835]:substance:"sulfaphenazole"
;[1840..1855]:substance:"tranylcypromine"
(SENT
  (S
    (NP-SBJ
      (NP (JJ:[1772..1777] Other) (NNS:[1778..1788] inhibitors))
      (,:[1788..1789] ,)
      (PP (JJ:[1790..1794] such) (IN:[1795..1797] as)
        (NP (NN:[1799..1819] alpha-naphthoflavone) (,:[1819..1820] ,)
            (NN:[1821..1835] sulfaphenazole) (CC:[1836..1839] and)
            (NN:[1840..1855] tranylcypromine))))
    (VP (VBD:[1856..1859] had)
      (NP
        (NP
          (NP
            (ADJP (RB:[1860..1864] very) (JJ:[1865..1871] little))
            (NML-1 (-NONE-:[1871..1871] *P*)))
          (CC:[1872..1874] or)
          (NP (DT:[1875..1877] no)
            (NML-1 (NN:[1879..1885] effect))))
        (PP (IN:[1886..1888] on)
          (NP (DT:[1889..1892] the) (NN:[1893..1901] activity)))))
    (.:[1901..1902] .)))

;sentence 14 Span:1903..2018
;The apparent Km for 6alpha-hydroxylation of  taurochenodeoxycholic by human
;liver microsomes was high (716 microM).
;[1916..1918]:quantitative-name:"Km"
;[1948..1969]:substance:"taurochenodeoxycholic"
;[2006..2009]:quantitative-value:"716"
;[2010..2016]:quantitative-units:"microM"
(SENT
  (S
    (NP-SBJ
      (NP (DT:[1903..1906] The) (JJ:[1907..1915] apparent) (NN:[1916..1918] Km))
      (PP (IN:[1919..1922] for)
        (NP
          (NP (NN:[1923..1943] 6alpha-hydroxylation))
          (PP (IN:[1944..1946] of)
            (NP (JJ:[1948..1969] taurochenodeoxycholic)))
          (PP (IN:[1970..1972] by)
            (NP (JJ:[1973..1978] human) (NN:[1979..1984] liver)
                (NNS:[1985..1995] microsomes))))))
    (VP (VBD:[1996..1999] was)
      (ADJP-PRD (JJ:[2000..2004] high)
        (PRN (-LRB-:[2005..2006] -LRB-)
          (NP (CD:[2006..2009] 716) (NN:[2010..2016] microM))
          (-RRB-:[2016..2017] -RRB-))))
    (.:[2017..2018] .)))

;sentence 15 Span:2019..2130
;This  might give an explanation for the limited formation of
;6alpha-hydroxylated bile  acids in healthy humans.
;[2100..2111]:substance:"bile  acids"
(SENT
  (S
    (NP-SBJ (DT:[2019..2023] This))
    (VP (MD:[2025..2030] might)
      (VP (VB:[2031..2035] give)
        (NP
          (NP (DT:[2036..2038] an) (NN:[2039..2050] explanation))
          (PP (IN:[2051..2054] for)
            (NP
              (NP (DT:[2055..2058] the) (VBN:[2059..2066] limited)
                  (NN:[2067..2076] formation))
              (PP (IN:[2077..2079] of)
                (NP
                  (ADJP (NN:[2080..2086] 6alpha) (HYPH:[2086..2087] -)
                        (VBN:[2087..2099] hydroxylated))
                   (NN:[2100..2104] bile) (NNS:[2106..2111] acids)))
              (PP-LOC (IN:[2112..2114] in)
                (NP (JJ:[2115..2122] healthy) (NNS:[2123..2129] humans))))))))
    (.:[2129..2130] .)))

;sentence 16 Span:2131..2300
;From the present results, it can be concluded that  CYP3A4 is active in the
;6alpha-hydroxylation of both taurochenodeoxycholic acid  and lithocholic acid
;in human liver.
;[2183..2189]:cyp450:"CYP3A4"
;[2236..2262]:substance:"taurochenodeoxycholic acid"
;[2268..2284]:substance:"lithocholic acid"
(SENT
  (S
    (PP (IN:[2131..2135] From)
      (NP (DT:[2136..2139] the) (JJ:[2140..2147] present)
          (NNS:[2148..2155] results)))
    (,:[2155..2156] ,)
    (NP-SBJ-1
      (NP (PRP:[2157..2159] it))
      (SBAR-2 (-NONE-:[2159..2159] *EXP*)))
    (VP (MD:[2160..2163] can)
      (VP (VB:[2164..2166] be)
        (VP (VBN:[2167..2176] concluded)
          (NP-1 (-NONE-:[2176..2176] *))
          (SBAR-2 (IN:[2177..2181] that)
            (S
              (NP-SBJ (NN:[2183..2189] CYP3A4))
              (VP (VBZ:[2190..2192] is)
                (ADJP-PRD (JJ:[2193..2199] active))
                (PP (IN:[2200..2202] in)
                  (NP
                    (NP (DT:[2203..2206] the)
                        (NN:[2207..2227] 6alpha-hydroxylation))
                    (PP (IN:[2228..2230] of)
                      (NP (CC:[2231..2235] both)
                        (NP (JJ:[2236..2257] taurochenodeoxycholic)
                            (NN:[2258..2262] acid))
                        (CC:[2264..2267] and)
                        (NP (JJ:[2268..2279] lithocholic) (NN:[2280..2284] acid))))
                    (PP-LOC (IN:[2285..2287] in)
                      (NP (JJ:[2288..2293] human) (NN:[2294..2299] liver)))))))))))
    (.:[2299..2300] .)))

;section 17 Span:2304..2349
;PMID: 10216279 [PubMed - indexed for MEDLINE]
(SEC
  (FRAG (NNP:[2304..2308] PMID) (::[2308..2309] :) (CD:[2310..2318] 10216279)
        (-LRB-:[2319..2320] -LSB-) (NNP:[2320..2326] PubMed)
        (HYPH:[2327..2328] -) (NN:[2329..2336] indexed) (IN:[2337..2340] for)
        (NNP:[2341..2348] MEDLINE) (-RRB-:[2348..2349] -RSB-)))
